Navigation Links
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Date:2/13/2009

e compared with other EGFR-targeting cancer drugs. - Two of YM's licensees for nimotuzumab, Daiichi-Sankyo Co., Ltd. in Japan and Kuhnil Pharmaceutical Co. in Korea, initiated an 80-patient Phase II randomized, open-label trial evaluating nimotuzumab in patients with advanced or recurrent gastric cancer. - YM's licensee in Europe, Oncoscience AG, continued to enroll patients in a randomized Phase III study evaluating nimotuzumab in adult glioma patients and a randomized Phase IIb/IIIa trial in patients with advanced pancreatic cancer. - YM and YM USA continued to enroll children with progressive, diffuse, intrinsic pontine glioma (DIPG) into a Phase II trial at multiple sites in the US, Canada and Israel and recruitment could be completed in late calendar 2009 or early 2010. - YM continued to prepare its second late-stage product, AeroLEF(R), for further development internationally, with a current focus on establishing the registration pathway for the product in Europe and conducting discussions with potential partners.

Financial Results (CDN dollars)

Total revenue (out-licensing revenue and interest income) for the second quarter of fiscal 2009, ended December 31, 2008 was $2.2 million compared with $1.9 million for the second quarter of fiscal 2008, ended December 31, 2007. Total revenue for the first six months of fiscal 2009, ended December 31, 2008 was $3.9 million compared with $3.7 million for the first six months of fiscal 2008, ended December 31, 2007. The increase in revenue is due to the receipt of a US$500 thousand milestone payment from one of the Company's licensees.

General and administrative expenses were $1.2 million for the second quarter of fiscal 2009 compared with $2.1 million for the second quarter of fiscal 2008. General and administrative expenses were $2
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
2. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
3. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
5. BD Biosciences to Distribute FCS Express
6. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
7. Cell Biosciences Introduces Kits for Oncoprotein Analysis
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... ANY LAB TEST NOW(R), the first retail direct-access ... partnered with Atherotech, Inc., a Birmingham, Alabama-based CLIA-laboratory to ... an affordable price. The VAP Cholesterol Test is an ... people at risk and is the first cholesterol test ...
... Belgium, May 14 , - ... Accordance With the Law of May 2, 2007 , ... company,focused on the discovery and development of innovative treatments for ... update for,the three month period ending 31 March, 2009. , ...
... Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of ... May 14 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... in a Phase 2 clinical trial of its lead ...
Cached Biology Technology:VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 2VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 3ThromboGenics NV: Business Update 2ThromboGenics NV: Business Update 3ThromboGenics NV: Business Update 4ThromboGenics NV: Business Update 5ThromboGenics NV: Business Update 6ThromboGenics NV: Business Update 7VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5
(Date:7/10/2014)... diseases, such as Alzheimer,s disease, type 2 diabetes, ... common trait that proteins aggregate into long fibers ... have found that neither the amylin monomer precursors ... evidence using two-dimensional infrared (2D IR) spectroscopy has ... pathway that may explain toxicity, opening a window ...
(Date:7/10/2014)... New research from The University of Texas Health ... GameKeep it Real (IYG), a health education program designed ... can significantly reduce dating violence behaviors among minority youth. ... Prevention, 10 percent of high school youth are victims ... more than 20 percent are victims of emotional dating ...
(Date:7/10/2014)... predict that western Lake Erie will have a significant ... 2014 bloom season in late summer. However, the predicted ... intense bloom, and considerably less than the record-setting 2011 ... western basin and are classified by an estimate of ... , Harmful algal blooms (HABs) were common in western ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 3
... team of Duke Medicine researchers has engineered cartilage from induced ... use in tissue repair and studies into cartilage injury and ... in the journal the Proceedings of the National Academy ... or iPSCs, may be a viable source of patient-specific articular ...
... The Journal of Cell Biology shows how ... nerve cells to help prevent neurodegeneration. The findings could pave ... in patients with neurodegenerative diseases. In Lou Gehrig,s ... in stages, with axons deteriorating first and the cells themselves ...
... who have lost a substantial amount of weight after ... their siblings who were born before the weight loss ... weight loss that occur after the surgery have a ... according to a new study presented at the Canadian ...
Cached Biology News:Duke researchers engineer cartilage from pluripotent stem cells 2Stay-at-home transcription factor prevents neurodegeneration 2Obese moms give birth to heart healthier kids following bariatric surgery 2Obese moms give birth to heart healthier kids following bariatric surgery 3
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
B-FABP (FL-132)...
Roll of Mesh 5m x 25cm...
Biology Products: